We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

87 hedge funds and large institutions have $259M invested in iShares US Pharmaceuticals ETF in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

6% more capital invested

Capital invested by funds: $244M → $259M (+$14.7M)

1% more funds holding

Funds holding: 86 → 87 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.73% less ownership

Funds ownership: 111.31% → 109.58% (-1.7%)

Holders
87
Holders Change
+1
Holders Change %
+1.16%
% of All Funds
2.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
9
Increased
36
Reduced
25
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$6.2M
2
VKH
Virtu KCG Holdings
New York
+$2.82M
3
PAG
Pinnacle Advisory Group
Maryland
+$2.07M
4
Goldman Sachs
Goldman Sachs
New York
+$1.97M
5
AP
Advisors Preferred
Maryland
+$1.68M

Top Sellers

Rank Fund Capital Flow
1
CCMG
Clark Capital Management Group
Pennsylvania
-$7.92M
2
BCI
Brinker Capital Investments
Pennsylvania
-$7.22M
3
TRCT
Tower Research Capital (TRC)
New York
-$3.76M
4
Morgan Stanley
Morgan Stanley
New York
-$1.86M
5
Jane Street
Jane Street
New York
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
AP
26
Advisors Preferred
Maryland
$2.01M +$1.68M +38,946 +698%
PP
27
Patten & Patten
Tennessee
$1.91M -$18.1K -420 -1%
CFA
28
Cahill Financial Advisors
Minnesota
$1.69M +$2.58K +60 +0.2%
CS
29
Credit Suisse
Switzerland
$1.62M +$1.24M +28,845 +409%
CPC
30
Cookson Peirce & Co
Pennsylvania
$1.59M +$82.6K +1,920 +6%
DADC
31
D.A. Davidson & Co
Montana
$1.36M +$387 +9 +0%
PAG
32
Private Advisor Group
New Jersey
$1.17M -$44.5K -1,035 -4%
SI
33
SII Investments
Wisconsin
$1.15M +$100K +2,325 +10%
TRCT
34
Tower Research Capital (TRC)
New York
$1.14M -$3.76M -87,489 -77%
CAN
35
Cetera Advisor Networks
California
$1.08M +$211K +4,902 +26%
Stifel Financial
36
Stifel Financial
Missouri
$1.02M -$91.9K -2,136 -9%
VFS
37
VSR Financial Services
Kansas
$868K -$1.03K -24 -0.1%
ICOA
38
Investment Centers of America
North Dakota
$764K +$154K +3,585 +27%
NES
39
New England Securities
New York
$710K +$86.8K +2,019 +15%
AMG
40
Asset Management Group
Connecticut
$673K +$1.29K +30 +0.2%
WA
41
WESPAC Advisors
California
$640K -$303K -7,047 -33%
NPC
42
National Planning Corporation
California
$630K +$18.6K +432 +3%
Jane Street
43
Jane Street
New York
$584K -$1.01M -23,379 -64%
US Bancorp
44
US Bancorp
Minnesota
$581K – – –
ACM
45
Avalon Capital Management
California
$561K – – –
TYCC
46
Texas Yale Capital Corp
Florida
$503K – – –
PAS
47
Partnervest Advisory Services
California
$493K +$199K +4,629 +73%
SG Americas Securities
48
SG Americas Securities
New York
$481K +$93.3K +2,169 +25%
CB
49
Commerce Bank
Missouri
$470K +$197K +4,575 +78%
LSA
50
L & S Advisors
California
$461K -$427K -9,918 -49%
1
2
3 4

IHE Hedge Fund Activity: Q2 2014 in Review

87 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2014, worth a combined $259M — up 6% from $244M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IHE positions and 8 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Bank of America, adding an estimated $6.2M. The largest seller was Clark Capital Management Group, exiting entirely with an estimated $7.92M sold.

  • 87 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2014, up from 86 in Q1 2014.
  • Funds reported $259M of iShares US Pharmaceuticals ETF stock for Q2 2014, up 6% quarter-over-quarter.
  • 9 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2014 and 8 closed out, a net change of +1 holder.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2014 was Bank of America, an estimated $6.2M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2014 was Clark Capital Management Group, an estimated $7.92M sold.

Based on aggregated 13F filings for Q2 2014.